Back to search results
Active, not recruiting

Pancreatic Cancer

A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer

JBEG | {{ defaultRegistry.registryAnchorText }} NCT02734160 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The main purpose of this study is to evaluate the safety and efficacy of the study drug known as galunisertib administered in combination with the anti-programmed cell death-ligand 1 (PD-L1) antibody, durvalumab, in participants with refractory metastatic pancreatic cancer.

Time Commitment

The duration of your participation depends on how well your disease responds to the study treatment.

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria


Male Female


18+ years
  • Participants must have metastatic pancreatic cancer, confirmed by histology or cystology. Recurrence must be documented by diagnostic biopsy.

  • Participants must have had disease progression, been resistant, or intolerant to no more than 2 prior systemic regiments for locally advanced or metastatic pancreatic cancer.

  • Participants who have received prior neoadjuvant therapy and who now have metastatic disease must have received 1 of the following treatments for their metastatic disease: FOLFIRINOX, nanoparticle albumin-bound paclitaxel/gemcitabine, TS-1 (tegafur gimeracil oteracil potassium), irinotecan liposome injection/5-fluorouracil (5FU)/Leucovorin or single-agent gemcitabine prior to entering the study

  • For some parts of the study, participants must be willing to undergo a tumor biopsy or to provide an available archival tumor sample

  • Participants must use approved contraceptive methods

  • Participants must not have moderate or severe cardiovascular disease

Where to Participate

Where to Participate

Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
{{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
{{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
{{site.siteStatus | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.